337 related articles for article (PubMed ID: 29874936)
1. Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations.
Daizadeh I
Ther Innov Regul Sci; 2019 Mar; 53(2):264-269. PubMed ID: 29874936
[TBL] [Abstract][Full Text] [Related]
2. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
Eur J Health Econ; 2023 Nov; ():. PubMed ID: 37962724
[TBL] [Abstract][Full Text] [Related]
3. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases.
Miller KL; Fermaglich LJ; Maynard J
Orphanet J Rare Dis; 2021 Jun; 16(1):265. PubMed ID: 34107994
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development.
Mease C; Miller KL; Fermaglich LJ; Best J; Liu G; Torjusen E
Orphanet J Rare Dis; 2024 Feb; 19(1):86. PubMed ID: 38403586
[TBL] [Abstract][Full Text] [Related]
5. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
Kwok M; Foster T; Steinberg M
Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
[TBL] [Abstract][Full Text] [Related]
6. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
Panzer AD; Ingham M; Martin S; Chambers JD
J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
[No Abstract] [Full Text] [Related]
7. FDA Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals.
Herink MC; Irwin AN; Zumach GM
Pharmacotherapy; 2018 Sep; 38(9):967-980. PubMed ID: 30043413
[TBL] [Abstract][Full Text] [Related]
8. A Drug Discovery Perspective on FDA Expedited Development and Incentive Programs.
Brown DG
J Med Chem; 2024 Feb; 67(3):1690-1700. PubMed ID: 38233132
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act.
Fermaglich LJ; Miller KL
Orphanet J Rare Dis; 2023 Jun; 18(1):163. PubMed ID: 37353796
[TBL] [Abstract][Full Text] [Related]
10. Orphan drug development in alpha-1 antitypsin deficiency.
Trudzinski FC; Presotto MA; Buck E; Herth FJF; Ries M
Sci Rep; 2022 Sep; 12(1):15497. PubMed ID: 36109566
[TBL] [Abstract][Full Text] [Related]
11. Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.
Monge AN; Sigelman DW; Temple RJ; Chahal HS
JAMA Netw Open; 2022 Nov; 5(11):e2239336. PubMed ID: 36318210
[TBL] [Abstract][Full Text] [Related]
12. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
Kühler TC; Bujar M; McAuslane N; Liberti L
BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
[TBL] [Abstract][Full Text] [Related]
13. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
14. Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.
Pauwels K; Huys I; Casteels M; Larsson K; Voltz C; Penttila K; Morel T; Simoens S
Orphanet J Rare Dis; 2017 Feb; 12(1):36. PubMed ID: 28209180
[TBL] [Abstract][Full Text] [Related]
15. An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020.
Wang S; Yang Q; Deng L; Lei Q; Yang Y; Ma P; Men Y; Yung BC; Lee RJ; Zhang M; Li N
Drug Discov Today; 2022 May; 27(5):1236-1250. PubMed ID: 34971818
[TBL] [Abstract][Full Text] [Related]
16. Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.
Vokinger KN; Kesselheim AS
BMJ Open; 2019 Oct; 9(10):e028634. PubMed ID: 31601584
[TBL] [Abstract][Full Text] [Related]
17. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
Kesselheim AS; Wang B; Franklin JM; Darrow JJ
BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
[TBL] [Abstract][Full Text] [Related]
18. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
Mechler K; Mountford WK; Hoffmann GF; Ries M
Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
20. Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.
Lutz T; Lampert A; Hoffmann GF; Ries M
Orphanet J Rare Dis; 2016 May; 11(1):60. PubMed ID: 27176041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
